- Home
- ANAB vs TWFG Comparison
ANAB vs TWFG Comparison
Compare ANAB & TWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- TWFG
- Stock Information
- Founded
- ANAB 2005
- TWFG 2001
- Country
- ANAB United States
- TWFG United States
- Employees
- ANAB N/A
- TWFG N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- TWFG
- Sector
- ANAB Health Care
- TWFG
- Exchange
- ANAB Nasdaq
- TWFG NYSE
- Market Cap
- ANAB 621.1M
- TWFG 530.3M
- IPO Year
- ANAB 2017
- TWFG 2024
- Fundamental
- Price
- ANAB $23.41
- TWFG $35.37
- Analyst Decision
- ANAB Buy
- TWFG Buy
- Analyst Count
- ANAB 10
- TWFG 8
- Target Price
- ANAB $44.25
- TWFG $33.71
- AVG Volume (30 Days)
- ANAB 566.9K
- TWFG 120.7K
- Earning Date
- ANAB 08-04-2025
- TWFG 08-26-2025
- Dividend Yield
- ANAB N/A
- TWFG N/A
- EPS Growth
- ANAB N/A
- TWFG N/A
- EPS
- ANAB N/A
- TWFG N/A
- Revenue
- ANAB $111,872,000.00
- TWFG $211,440,000.00
- Revenue This Year
- ANAB N/A
- TWFG $23.90
- Revenue Next Year
- ANAB $24.39
- TWFG $22.60
- P/E Ratio
- ANAB N/A
- TWFG N/A
- Revenue Growth
- ANAB 387.20
- TWFG 18.57
- 52 Week Low
- ANAB $12.21
- TWFG $21.31
- 52 Week High
- ANAB $41.31
- TWFG $36.85
- Technical
- Relative Strength Index (RSI)
- ANAB 57.46
- TWFG N/A
- Support Level
- ANAB $21.87
- TWFG N/A
- Resistance Level
- ANAB $24.69
- TWFG N/A
- Average True Range (ATR)
- ANAB 1.19
- TWFG 0.00
- MACD
- ANAB -0.09
- TWFG 0.00
- Stochastic Oscillator
- ANAB 61.20
- TWFG 0.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.